Biosimilar Use in Cancer Treatment: Current Attitudes & Perceptions

DANIEL TURNER | September 21, 2019

article image
Biological drugs, protein-based products derived from living cells using biotechnology, have been used since the 1990’s as a treatment option for cancer patients. Since 2009, biosimilar therapies (therapeutically equivalent subsequent entry biologics) have been available in different therapeutic areas in Canada, and are now on the verge of becoming available for use in oncology. MD Analytics asked 31 Canadian Oncologists and Hematologists for their views on the introduction of biosimilar therapies for cancer treatment.

Spotlight

Cambridge Epigenetix

Cambridge Epigenetix Ltd is commercializing a novel technology that pioneers quantitative single-base resolution sequencing of the methylated bases 5-hmC and 5-mC leading to substantially more accurate determination of the methylated status of genomic DNA with relevance in research, pharmaceutical discovery and diagnostics.

OTHER ARTICLES

Biotech: Finding The DNA For Success

Article | April 3, 2020

The integration of artificial intelligence within life sciences is making drug discovery and development more innovative, less labor intensive and more cost-effective, says Deloitte’s annual global outlook. According to Deloitte’s 2020 Global Life Sciences Outlook, the biotech sector is at an inflection point. To prepare for the future and remain relevant in the ever-evolving business landscape, biopharma and medtech organizations will be looking for new ways to create value and new metrics to make sense of today’s wealth of data, the report overview says. As data-driven technologies provide biopharma and medtech organizations with treasure troves of information, and automation takes over some mundane tasks, new talent models are emerging based on purpose and meaning. The integration of artificial intelligence (AI) and machine learning approaches within life sciences is making drug discovery and development more innovative, time-effective and cost-effective, the Deloitte report states.

Read More

Learning How FoxA2 Helps Turn Stem Cells into Organs

Article | April 3, 2020

Scientists at the Perelman School of Medicine at the University of Pennsylvania discovered early on in each cell, FoxA2 simultaneously binds to both the chromosomal proteins and the DNA, opening the flood gates for gene activation. The discovery, “Gene network transitions in embryos depend upon interactions between a pioneer transcription factor and core histones,” published in Nature Genetics, helps untangle mysteries of how embryonic stem cells develop into organs, according to the researchers. “Gene network transitions in embryos and other fate-changing contexts involve combinations of transcription factors. A subset of fate-changing transcription factors act as pioneers; they scan and target nucleosomal DNA and initiate cooperative events that can open the local chromatin. However, a gap has remained in understanding how molecular interactions with the nucleosome contribute to the chromatin-opening phenomenon,” write the investigators.

Read More

Top 10 biotech IPOs in 2019

Article | April 3, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
MEDICAL

Better Purification and Recovery in Bioprocessing

Article | April 3, 2020

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More

Spotlight

Cambridge Epigenetix

Cambridge Epigenetix Ltd is commercializing a novel technology that pioneers quantitative single-base resolution sequencing of the methylated bases 5-hmC and 5-mC leading to substantially more accurate determination of the methylated status of genomic DNA with relevance in research, pharmaceutical discovery and diagnostics.

Events